|
Learn validated clinical tools that can be integrated into busy clinical practices and
clinical pearls for managing patients already on chronic opioid therapy.
Tuition: $25
Target Audience: physicians, advance practice nurses, physician assistants,
nurses, dentists, pharmacists and allied healthcare professionals
SCOPE of Pain Milford is provided by Boston University School of Medicine, with local partners
Milford Hospital, Milford Prevention Council, the Connecticut Opioid
Response Initiative, the Yale School of Medicine, and the New England High
Intensity Drug Trafficking Area Program. National collaborators include the
Council of Medical Specialty Societies and the Federation of State Medical
Boards.
Why offer this training? The FDA has mandated manufacturers of extended
release/long-acting (ER/LA) opioid analgesics, as part of a comprehensive
Risk Evaluation and Mitigation Strategy (REMS), to make available
comprehensive prescriber education in the safe use of these medications.
Our training is based on the FDA curriculum known as the Blueprint for Prescriber
Education for Extended Release and Long-Acting Opioid (ER/LA) Analgesics.
Our curriculum covers all aspects of this blueprint and more to provide a
comprehensive educational program.
Course Director and Speaker:
Daniel P. Alford,
MD, MPH | Professor of Medicine, Boston University School
of Medicine
Faculty:
William Becker, MD
| Associate Professor, Yale University School of Medicine
Daniel G. Tobin,
MD, FACP | Associate Professor, Yale University School of
Medicine
Medical Director, Yale Primary Care
Provided by:
Planned in
collaboration with:
Accreditation
Physicians
This activity has been planned and implemented in accordance
with the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of Boston University School of Medicine with local partners
Milford Hospital, Milford Prevention Council, the Connecticut Opioid
Response Initiative, the Yale School of Medicine, and the New England High
Intensity Drug Trafficking Area Program. Boston University School of
Medicine is accredited by the ACCME to provide continuing medical education
for physicians.
Boston University School of Medicine designates this live activity for a
maximum of 3.25 AMA
PRA Category 1 Credits™. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
Nurses
Continuing Nursing Education Provider Unit, Boston
University School of Medicine is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center’s Commission
on Accreditation. CNE Contact Hours: 3.25, all of which is
pharmacology credit-worthy
AAFP
This Live activity, SCOPE of Pain: Safe & Competent
Opioid Prescribing Education, from 12/7/17 - 12/7/18, has been reviewed and
is acceptable for up to 2.00 Prescribed credits by the American Academy of
Family Physicians. Physicians should claim only the credit commensurate
with the extent of their participation in the activity., has been reviewed
and is acceptable for up to 2.00 Prescribed credits by the American Academy
of Family Physicians. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
ABIM MOC Part II
Successful completion of this CME activity, which includes
participation in the evaluation component, enables the participant to earn
2 MOC points and patient safety MOC credit in the American Board of
Internal Medicine’s (ABIM) Maintenance of Certification (MOC)
program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting
ABIM MOC credit.
Disclosure of Support
This educational activity is supported by an independent
educational grant from the Extended-Release/Long-Acting Opioid Analgesic
REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf
for a listing of REMS Program Companies. This activity is intended to be
fully compliant with the Extended-Release/Long-Acting Opioid Analgesics
REMS education requirements issued by the US Food & Drug
Administration.
|
